Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneReach BiotechnologyROCO:4171 -1.81%58 Debt-to-EBITDA is 5.77 as of Jun. 2026, which is 831% above its 10-year median of 0.62. GuruFocus rates ROCO:4171 with a GF Score™ of 58/100 and a GF Value™ of NT$26.01 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 304 Biotechnology companies, GeneReach Biotechnology ranks worse than 89.14% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for GeneReach Biotechnology's Debt-to-EBITDA or its related term are showing as below:
ROCO:4171'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -13.64 Med: 0.62 Max: 208.65
Current: 13.66
During the past 13 years, the highest Debt-to-EBITDA Ratio of GeneReach Biotechnology was 208.65. The lowest was -13.64. And the median was 0.62.
ROCO:4171's Debt-to-EBITDA is ranked worse than 89.14% of 304
companies
in the Biotechnology industry
Industry Median: 1.255
vs ROCO:4171: 13.66
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
GeneReach Biotechnology Debt-to-EBITDA Related Terms
GeneReach Biotechnology Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4171 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, GeneReach Biotechnology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneReach Biotechnology Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GeneReach Biotechnology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GeneReach Biotechnology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
GeneReach Biotechnology (ROCO:4171) has a Debt-to-EBITDA of 5.77 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GeneReach Biotechnology. This is 831% above median its historical median of 0.62. According to the industry distribution chart, GeneReach Biotechnology ranks #271 out of 304 companies in the Biotechnology industry, placing it in the top 89.1%.
Is GeneReach Biotechnology's Debt-to-EBITDA too high?
GeneReach Biotechnology's current Debt-to-EBITDA of 5.77 is 831% above median its 10-year median of 0.62. The Biotechnology industry median Debt-to-EBITDA is 1.26. GeneReach Biotechnology's value of 5.77 is 359.8% above this industry median. Based on the distribution chart, GeneReach Biotechnology ranks #271 out of 304 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GeneReach Biotechnology has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GeneReach Biotechnology's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GeneReach Biotechnology ranks #271 out of 304 companies for Debt-to-EBITDA. This places GeneReach Biotechnology in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. GeneReach Biotechnology's value of 5.77 is 359.8% above this benchmark. While the company's 10-year median is 0.62 vs. the industry median of 1.26, GeneReach Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneReach Biotechnology's current Debt-to-EBITDA of 5.77 is 359.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GeneReach Biotechnology. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneReach Biotechnology's current Debt-to-EBITDA is 5.77, which is 831% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneReach Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, GeneReach Biotechnology (ROCO:4171) is currently considered Possible Value Trap. The stock's GF Value™ is NT$26.01, compared to a current price of NT$16.30 — trading 37.3% below its estimated fair value. The current Debt-to-EBITDA is 5.77, which is 831% above median its 10-year median of 0.62 and 359.8% above the Biotechnology industry median of 1.26. GeneReach Biotechnology's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For GeneReach Biotechnology (ROCO:4171), the current Debt-to-EBITDA is 5.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneReach Biotechnology (ROCO:4171) Overvalued in 2026?
Based on GuruFocus' analysis, GeneReach Biotechnology stock appears to be undervalued.
The current stock price of NT$16.30 is trading 37.3% below its estimated GF Value™ of NT$26.01.
GuruFocus considers GeneReach Biotechnology to be Possible Value Trap.
Key valuation signals for ROCO:4171:
Debt-to-EBITDA: 5.77 (831% above median its 10-year median of 0.62)
GF Value™: NT$26.01 vs. price of NT$16.30 (37.3% below fair value)
Industry Position: 359.8% above the Biotechnology median (#271 of 304)
No single metric tells the full story. See the ROCO:4171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneReach Biotechnology Corp is a biotechnology company. The company develops, manufactures and markets products for applied nucleic acid detection technology. Its products are utilised for aquaculture, agriculture, food, companion animal, livestock and human health industries.
58GF Score
Get the complete analysis for ROCO:4171
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4171 has been successfully added to your 
